Utah 2025 Regular Session

Utah House Bill HB0548

Introduced

2/25/25

Refer

2/27/25

Report Pass

3/3/25

Engrossed

3/3/25

Failed

3/7/25

Caption

Genetic Information Amendments

Impact

One of the significant impacts of HB 0548 is the requirement for entities handling genetic data to comply with stringent security measures, including the use of encryption and limiting access to sensitive data. Facilities must ensure they are not using prohibited genetic sequencers, which could lead to significant operational changes. The bill mandates that compliance be confirmed annually through sworn statements submitted to the attorney general, and violations can lead to substantial fines, signaling an increased state oversight in genetic data management.

Summary

House Bill 0548, titled 'Genetic Information Amendments', establishes regulations regarding the use of genetic sequencing tools and the storage of genetic sequencing data. The bill aims to prohibit medical and genomic research facilities from utilizing specific genetic sequencers and software produced by foreign adversaries. The legislation provides a framework to ensure that sensitive genetic data is not stored within the jurisdictions of foreign adversaries, thereby enhancing data security and safeguarding the integrity of genetic information.

Sentiment

The sentiment surrounding the bill appears generally supportive among legislators focused on cybersecurity and data protection. Proponents argue that the measures outlined in the bill are necessary to prevent unauthorized access to sensitive genetic information and maintain national security. However, there may be concerns regarding the potential for increased regulatory burden on medical and research facilities, which some critics might view as an overreach that complicates their operations.

Contention

Notable points of contention likely revolve around the broad definitions of 'foreign adversaries' and the stipulations on data storage and equipment usage. Discussions may highlight potential challenges in enforcement and compliance, particularly regarding which entities fall under the restrictions and how facilities will adapt to these regulations. Critics could argue that such measures may inadvertently limit research capabilities or drive up costs for healthcare providers, prompting debates over the balance between security and innovation in genetic research.

Latest HB0548 Activity

Companion Bills

No companion bills found.

Similar Bills

CA AB1103

Controlled substances: research.

US SB331

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl ActThis bill permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.Under the bill, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term).Additionally, the bill establishes a new, alternative registration process for certain schedule I research.The bill also makes several other changes to registration requirements for conducting research with controlled substances, includingpermitting a single registration for related research sites in certain circumstances,waiving the requirement for a new inspection in certain situations, andallowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.Finally, the bill expresses the sense that Congress agrees with the interpretation of the Controlled Substances Act in United States v. McCray, a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.

US HB27

Halt All Lethal Trafficking of Fentanyl Act or the HALT Fentanyl ActThis bill permanently places fentanyl-related substances as a class into schedule I of the Controlled Substances Act. A schedule I controlled substance is a drug, substance, or chemical that has a high potential for abuse; has no currently accepted medical value; and is subject to regulatory controls and administrative, civil, and criminal penalties under the Controlled Substances Act.Under the bill, offenses involving fentanyl-related substances are triggered by the same quantity thresholds and subject to the same penalties as offenses involving fentanyl analogues (e.g., offenses involving 100 grams or more trigger a 10-year mandatory minimum prison term).Additionally, the bill establishes a new, alternative registration process for certain schedule I research.The bill also makes several other changes to registration requirements for conducting research with controlled substances, includingpermitting a single registration for related research sites in certain circumstances,waiving the requirement for a new inspection in certain situations, andallowing a registered researcher to perform certain manufacturing activities with small quantities of a substance without obtaining a manufacturing registration.Finally, the bill expresses the sense that Congress agrees with the interpretation of Controlled Substances Act in United States v. McCray, a 2018 case decided by the U.S. District Court for the Western District of New York. In that case, the court held that butyryl fentanyl, a controlled substance, can be considered an analogue of fentanyl even though, under the Controlled Substances Act, the term controlled substance analogue specifically excludes a controlled substance.